[HTML][HTML] The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
I Ullah, G Beaudoin-Bussières, K Symmes… - Cell Reports …, 2023 - cell.com
Summary COVID-19 convalescent plasmas (CCPs) are chosen for plasma therapy based on
neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that …
neutralizing titers and anti-Spike immunoglobulin levels. However, CCP characteristics that …
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
T Hueso, C Pouderoux, H Péré… - Blood, The Journal …, 2020 - ashpublications.org
Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological
malignancies or autoimmune disease but may be responsible for a secondary humoral …
malignancies or autoimmune disease but may be responsible for a secondary humoral …
Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID‐19 patients with pneumonia
S De Biasi, D Lo Tartaro, M Meschiari… - European journal of …, 2020 - Wiley Online Library
Studies on the interactions between SARS‐CoV‐2 and humoral immunity are fundamental
to elaborate effective therapies including vaccines. We used polychromatic flow cytometry …
to elaborate effective therapies including vaccines. We used polychromatic flow cytometry …
[HTML][HTML] Reactive T cells in convalescent COVID-19 patients with negative SARS-CoV-2 antibody serology
S Steiner, T Schwarz, VM Corman, F Sotzny… - Frontiers in …, 2021 - frontiersin.org
Despite RT-PCR confirmed COVID-19, specific antibodies to SARS-CoV-2 spike are
undetectable in serum in approximately 10% of convalescent patients after mild disease …
undetectable in serum in approximately 10% of convalescent patients after mild disease …
[HTML][HTML] Imbalanced immune response of T-cell and B-cell subsets in patients with moderate and severe COVID-19
A Golovkin, O Kalinina, V Bezrukikh, A Aquino… - Viruses, 2021 - mdpi.com
Background: The immunological changes associated with COVID-19 are largely unknown.
Methods: Patients with COVID-19 showing moderate (n= 18; SpO2> 93%, respiratory rate> …
Methods: Patients with COVID-19 showing moderate (n= 18; SpO2> 93%, respiratory rate> …
One-year sustained cellular and humoral immunities in coronavirus disease 2019 (COVID-19) convalescents
J Zhang, H Lin, B Ye, M Zhao, J Zhan… - Clinical Infectious …, 2022 - academic.oup.com
Background The longitudinal antigen-specific immunity in COVID-19 convalescents is
crucial for long-term protection upon individual re-exposure to SARS-CoV-2, and even more …
crucial for long-term protection upon individual re-exposure to SARS-CoV-2, and even more …
[HTML][HTML] Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases
R Carsetti, S Zaffina, E Piano Mortari, S Terreri… - Frontiers in …, 2020 - frontiersin.org
SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum
of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to …
of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to …
Convalescent plasma therapy for the treatment of patients with COVID‐19: assessment of methods available for antibody detection and their correlation with …
Introduction The lack of approved specific therapeutic agents to treat coronavirus disease
(COVID‐19) associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV …
(COVID‐19) associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV …
Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial
MLL Madariaga, JJ Guthmiller… - Journal of internal …, 2021 - Wiley Online Library
Background Convalescent plasma therapy for COVID‐19 relies on transfer of anti‐viral
antibody from donors to recipients via plasma transfusion. The relationship between clinical …
antibody from donors to recipients via plasma transfusion. The relationship between clinical …
[HTML][HTML] Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
J Boonyaratanakornkit, C Morishima… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND SARS-CoV-2–specific antibodies may protect from reinfection and disease,
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …
providing rationale for administration of plasma containing SARS-CoV-2–neutralizing …